Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3074% below fair value
$5.61−0.20 (-3.44%)
Close on Nov 17, 2026Market cap $287.64MP/E –Yield –
Emergent BioSolutions total assets
Total assets on the balance sheet at the end of each period.
Emergent BioSolutions's total assets was $995.20M at Sep 30, 2026. For fiscal 2025 it was $1.32B, down 5.1% from the year before. Over ten years it grew 2.4% a year on average. The highest annual figure on record is $3.17B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32B | -5.1% |
| FY2024 | Dec 31, 2024 | $1.39B | -23.8% |
| FY2023 | Dec 31, 2023 | $1.82B | -42.4% |
| FY2022 | Dec 31, 2022 | $3.17B | +7.1% |
| FY2021 | Dec 31, 2021 | $2.96B | +2.6% |
| FY2020 | Dec 31, 2020 | $2.88B | +23.9% |
| FY2019 | Dec 31, 2019 | $2.33B | +4.4% |
| FY2018 | Dec 31, 2018 | $2.23B | +108.3% |
| FY2017 | Dec 31, 2017 | $1.07B | +10.3% |
| FY2016 | Dec 31, 2016 | $970.11M | -6.5% |
| FY2015 | Dec 31, 2015 | $1.04B | +10.5% |
| FY2014 | Dec 31, 2014 | $938.69M | +49.8% |
| FY2013 | Dec 31, 2013 | $626.63M | +11.1% |
| FY2012 | Dec 31, 2012 | $564.23M | +3.2% |
| FY2011 | Dec 31, 2011 | $546.86M | +9.3% |
| FY2010 | Dec 31, 2010 | $500.32M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $995.20M | -31.9% |
| Q2 FY2026 | Jun 30, 2026 | $1.12B | -21.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.32B | -7.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.32B | -5.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.46B | -1.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.42B | -6.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.43B | -20.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.39B | -23.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.48B | -21.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.51B | -30.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.80B | -38.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.82B | -42.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.89B | -34.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.18B | -20.3% |
| Q1 FY2023 | Mar 31, 2023 | $2.95B | +6.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.17B | +7.1% |
| Q3 FY2022 | Sep 30, 2022 | $2.90B | +1.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.74B | -6.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.78B | -4.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.96B | +2.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.87B | +9.6% |
| Q2 FY2021 | Jun 30, 2021 | $2.92B | +18.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.90B | +27.3% |
| Q4 FY2020 | Dec 31, 2020 | $2.88B | +23.9% |
| Q3 FY2020 | Sep 30, 2020 | $2.62B | +12.1% |
| Q2 FY2020 | Jun 30, 2020 | $2.47B | +6.2% |
| Q1 FY2020 | Mar 31, 2020 | $2.28B | +5.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.33B | +4.4% |
| Q3 FY2019 | Sep 30, 2019 | $2.33B | +98.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.32B | +103.8% |
| Q1 FY2019 | Mar 31, 2019 | $2.15B | +101.6% |
| Q4 FY2018 | Dec 31, 2018 | $2.23B | +108.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.17B | +14.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.14B | +17.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.07B | +12.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.07B | +10.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.02B | – |
| Q2 FY2017 | Jun 30, 2017 | $970.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $951.64M | – |
| Q4 FY2016 | Dec 31, 2016 | $970.11M | – |
See a number that looks wrong?